Single answer
Is Aktis Oncology Inc (AKTS) a buy or sell?
4starter turns market data into one clear verdict you can act on.
Create a free account to save tickers and track your signals.
Log in to turn on watchlist alerts.
Decision snapshot
Everything you need to act fast, in one glance.
What is the conclusion?
Right now our advanced algorithms say:
$1 invested is now $1.02 or 2.37%
(In 6 weeks 2 days 16 hours 26 minutes and 59 seconds .)
Do analysts agree?
We compare consensus targets with today's price.
Consensus target for Aktis Oncology Inc is $31.00, which is $11.50 (58.97%) above the current price today's price.
Low target: $31.00 | High target: $31.00
Latest analyst updates
Recent rating and price target changes for this stock.
Company snapshot
A quick overview of the business and its public profile.
Aktis Oncology Inc operates as a clinicalstage oncology company that engages in the development of targeted radiopharmaceutical therapies for cancer treatment The company offers a miniprotein radioconjugate platform to discover and develop radiopharmaceutical therapies that deliver the tumorkilling properties of radioisotopes It offers Nectin4 a miniprotein radioconjugate for the treatment of locally advanced or metastatic urothelial cancer Its products include AKY1189 to deliver a radioisotope to Nectin4 expressing tumors for the treatment of metastatic urothelial cancer breast cancer NSCLC colorectal cancer and cervical cancer and AKY2519 to deliver radioisotope to B7H3 CD276 expressing tumors targeting prostate lung and other solid tumors The company was formerly known as HotKnot Therapeutics Inc and changed its name to Aktis Oncology Inc in April 2020 Aktis Oncology Inc was incorporated in 2020 and is based in Boston Massachusetts
Website: https://www.aktisoncology.com
Rates and inflation backdrop
US inflation for January 2026 was 0.17%. Over the last 12 months, inflation is 2.83%. The 10-year yield is 4.04 and is down -0.110 over the last 30 days.
Inflation sensitivity
Debt ratio: 0.04. Cash flow to debt ratio: 1.23. Net profit margin: -2,957.63%. Inflation risk score: low (0.40/1).
Dividend history check
We cannot find any recorded dividends paid in our systems.
Trading liquidity
Yes, the average daily trading liquidity for Aktis Oncology Inc is $2.7M. You should therefore be able to get in and out of your positions relatively fast.
10-year return check
On Aktis Oncology Inc, 2016-02-26 had a stock price of $1.550. If you invested back then, your return now would be a profit of $17.95 per share or 1,158.06%.
Why this answer
We combine price momentum, volatility, and trend signals to simplify the decision to one word.
Signal engine scans price, trend, and momentum indicators.
Targets and sentiment are checked against the live quote.
We keep the output simple: buy, sell, or hold.
Analyst consensus
How Wall Street targets compare to today's price.